{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-24-125307","form_type":"8-K","ticker":"FATE","cik":"0001434316","company_name":"FATE THERAPEUTICS INC","filed_at":"2024-11-12T23:59:59+00:00","discovered_at":"2026-05-14T18:03:08.441011+00:00","generated_at":"2026-05-30T01:43:04.660894+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"Fate Therapeutics Q3 rev $3.1M, cash $330.5M; FT819/FT522/FT825 clinical progress","bullets":["Q3 revenue of $3.1M from Ono collaboration; total op expense $55.5M incl $11.8M stock comp.","Cash, equivalents & investments $330.5M; projected operating runway through end of 2026.","FT819 Phase 1 SLE: 3 patients dosed with fludarabine-free conditioning; no DLTs/CRS/ICANS/GvHD; data at ACR and ASH.","FT522 IND allowed for B cell-mediated autoimmune basket study; initial BCL clinical data at ACR Convergence.","FT825/ONO-8250 initial solid tumor data: safety profile favorable, CAR T expansion with activated phenotype at 100M dose."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-24-125307","json":"https://secwatch.observer/filing/0000950170-24-125307.json","markdown":"https://secwatch.observer/filing/0000950170-24-125307.md","text":"https://secwatch.observer/filing/0000950170-24-125307.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1434316/000095017024125307/0000950170-24-125307-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1434316/000095017024125307/fate-20241112.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-30T01:43:04.660894+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}